Gujarat Themis Biosyn Limited — Important, 22-05-2026: Agreements

Gujarat Themis Biosyn (GTBL) is acquiring 100% of Japan's MicroBiopharm Japan (MBJ) for ~INR 1,300 Cr. MBJ, a pharma CDMO with ~INR 570 Cr FY26E revenue, enhances GTBL's strategy to become a tech-driven CDMO in precision fermentation and biotechnology.